Loading stock data…
Embecta Corp (EMBC)
$3.31-0.18 (-5.16%)
Market ClosedLast close Jun 29
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Embecta Corp. in the Healthcare sector is trading at $3.31 with a market capitalization of $183M. Wall Street consensus targets $4.00 (2 analysts), implying a +20.8% move over the next 12 months. The stock is currently near its 52-week low of $2.77, remaining 66.6% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +20.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $221.80M↓ | $261.20M↓ | $264.00M↓ | $295.50M↑ | $259.00M |
| Gross Profit | $127.80M↓ | $161.70M↑ | $158.50M↓ | $197.10M↑ | $164.10M |
| Operating Income | $42.90M↓ | $76.30M↑ | $64.30M↓ | $105.00M↑ | $73.70M |
| Net Income | -$4.10M↓ | $44.10M↑ | $26.40M↓ | $45.50M↑ | $23.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection device...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$183.32M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
13.60%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.87%
Volume
Today's trading volume
1.76M
Recent News
Embecta (EMBC) Hit With A Sharp Target Cut As Medtech Sentiment Weakens
With an upside potential of 32.01%, Embecta Corp. (NASDAQ:EMBC) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 18, Bank of America analyst Travis Steed lowered the firm’s price target on Embecta Corp. (NASDAQ:EMBC) to $3 from $11 while maintaining an Underperform rating on the shares. Following meetings with […]
Embecta acquires Owen Mumford for $172.6m
The transaction supports Embecta’s plan to diversify by supplying drug delivery solutions to pharmaceutical partners.
Embecta closes Owen Mumford acquisition for up to $201M
Embecta bought the company, which has an auto-injector platform, to expand outside of diabetes care.
Embecta Faces U.S. Reset as CEO Bets on GLP-1, Owen Mumford Diversification
Embecta (NASDAQ:EMBC) President and CEO Devdatt Kurdikar said the company’s recent U.S. business reset reflected a combination of customer-specific share loss, softer market trends and inventory-related factors, while emphasizing that the diabetes device maker is continuing a broader diversification
S&P Global Ratings Cuts Credit Rating on Embecta (EMBC) After Revenue Decline
Embecta Corp. (NYSE:EMBC) is included among the 12 Best Micro-Cap Dividend Stocks to Buy Now. On May 12, S&P Global Ratings lowered its issuer credit rating on Embecta Corp. (NYSE:EMBC) to ‘B’ from ‘B+’. The agency pointed to weaker operating performance, increasing competitive pressure, and softer-than-expected fiscal 2026 guidance. It also downgraded the company’s senior […]